Abstract
The effects of a water-soluble tacrolimus-PEG conjugate (KI-102) on insulin-dependent diabetes mellitus and systemic lupus erythematosus were investigated. KI-102 was stable at pH 4.0–4.5 and 4°C. The area under the concentration-time curve, the time of maximum concentration, and the maximum concentration were 43.4 ng·h/mL, 0.85 h, and 8.1 ng/mL, respectively, similar to those of FK506. Mice that administered KI-102 at 4.32 mg/kg had the plasma glucose concentrations that decreased to 7.5 mmol/L after 170 days, similar to that of mice administered FK506 at 0.6 mg/kg. There were no incidences of diabetes when KI-102 was administered at 86.4 mg/kg after 24 weeks. The group that administered 43.2 mg/kg had decreases in the concentrations of β-hydroxybutyrate (60%), triglyceride (24%), and cholesterol (30%). KI-102 administered at 180 mg/kg reduced serum anti-dsDNA antibody activity by 64% compared with a control. Urinary albumin concentration in the same group decreased 81% compared with the control. These results indicate that KI-102 may be practically applicable as prodrug of FK506.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Besarab, A., Jarrell, B. E., Hirsch, S., Carabasi, R. A., Cressman, M. D., and Green, P., Use of the isolated perfused kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, cremophor EL. Transplantation, 44, 195–201 (1987).
Choi, D. and Cho, H., Effect of tacrolimus derivatives on immunosuppression. Arch. Pharm. Res., 32, 549–557 (2009).
Chung, Y. and Cho, H., Preparation of highly water soluble tacrolimus derivatives: poly(ethylene glycol) esters as potential prodrugs. Arch. Pharm. Res., 27, 878–883 (2004).
Fung, J. J., Tacrolimus and transplantation: a decade in review. Transplantation, 77, S41–S43 (2004).
Hane, K., Fujioka, M., Namiki, Y., Kitagawa, T., Kihara, N., Shimatani, K., and Yasuda, T., Physico-chemical properties of FK-506. Iyakuhin Kenkyu, 23, 33–43 (1992).
Harris, J. M. and Chess, R. B., Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2, 214–221 (2003).
Kim, H. S. and Park, Y. I., Isolation and identification of a novel microorganism producing the immunosuppressant tacrolimus. J. Biosci. Bioeng., 105, 418–421 (2008).
Koo, J. Y., Fleischer, A. B. Jr., Abramovits, W., Pariser, D. M., McCall, C. O., Horn, T. D., Gottlieb, A. B., Jaracz, E., and Rico, M. J., Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J. Am. Acad. Dermatol., 53, S195–S205 (2005).
Kremer, J. M., Habros, J. S., Kolba, K. S., Kaine, J. L., Borton, M. A., Mengle-Gaw, L. J., Schwartz, B. D., Wisemandle, W., and Mekki, Q. A., Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum., 48, 2763–2768 (2003).
Mathew, A. E., Mejillano, M. R., Nath, J. P., Himes, R. H., and Stella, V. J., Synthesis and evaluation of some watersoluble prodrugs and derivatives of taxol with antitumor activity. J. Med. Chem., 35, 145–151 (1992).
Mattila, P. S., Ullman, K. S., Fiering, S., Emmel, E. A., McCutcheon, M., Crabtree, G. R., and Herzenberg, L. A., The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. EMBO J., 9, 4425–4433 (1990).
Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., and Maeda, H., Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res., 89, 307–314 (1998).
Peters, D. H., Fitton, A., Plosker, G. L., and Faulds, D., Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs, 46, 746–794 (1993).
Shafiee, A., Motamedi, H., and Chen, T., Enzymology of FK-506 biosynthesis. Purification and characterization of 31-O-desmethylFK-506 O: methyltransferase from Streptomyces sp. MA6858. Eur. J. Biochem., 225, 755–764 (1994).
Snyder, S. H. and Sabatini, D. M., Immunophilins and the nervous system. Nat. Med., 1, 32–37 (1995).
Tanaka, H., Kuroda, A., Marusawa, H., Hatanaka, H., Kino, T., Koto, T., Hashmoto, M., and Taga, T., Structure of FK-506: a novel immunosuppressant isolated from Streptomyces. J. Am. Chem. Soc., 109, 5031–5033 (1987).
Yocum, D. E., Furst, D. E., Kaine, J. L., Baldassare, A. R., Stevenson, J. T., Borton, M. A., Mengle-Gaw, L. J., Schwartz, B. D., Wisemandle, W., and Mekki, Q. A., Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum., 48, 3328–3337 (2003).
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Choi, D., Kim, B.H., Lee, M.K. et al. Effects of water-soluble tacrolimus-PEG conjugate on insulin-dependent diabetes mellitus and systemic lupus erythematosus. Arch. Pharm. Res. 34, 1301–1310 (2011). https://doi.org/10.1007/s12272-011-0810-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-0810-z